Tags

Type your tag names separated by a space and hit enter

[The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients].
Neurologia. 1997 Apr; 12(4):145-56.N

Abstract

This is a multicentric double blind comparison of the effects of standard and slow release levodopa + carbidopa formulations in patients with Parkinson's disease. Sixty four patients with simple fluctuations were included and 43 finished the study. The study had three phases: a) optimal dose findings phase with standard levodopa + carbidopa; b) open label, cross over study with the two formulations, and c) double blind, parallel investigation. The following results were obtained. There was not a difference in the severity of disability according to UPDRS, part 3, scores though the subjective impressions of patients were in favor of standard formulations. The Sustained release levodopa + carbidopa produced significant improvement of dystonia in off period, pain due to akinesia in off and the number of hours in off and the quality and latency of sleep. In addition there was a tendency in favor of slow release compounds for early morning akinesia, global effect and impression of the examining physician. Low protein diet improved the kinetics of levodopa and the clinical response with both formulations. The clinical usefulness of standard and slow release levodopa + carbidopa formulation should be weighted according to individual problems of patients with Parkinson's disease.

Authors+Show Affiliations

Servicio de Neurología, Fundación Jiménez Díaz, Madrid.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't

Language

spa

PubMed ID

9235023

Citation

García de Yébenes, J, et al. "[The Effect of Controlled Release of DOPA and Carbidopa On Clinical Response and Plasma Pharmacokinetics of DOPA in Parkinsonian Patients]." Neurologia (Barcelona, Spain), vol. 12, no. 4, 1997, pp. 145-56.
García de Yébenes J, Mateo D, Pino MA, et al. [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]. Neurologia. 1997;12(4):145-56.
García de Yébenes, J., Mateo, D., Pino, M. A., Cordero, M., Pastor, M., Chacón, J., Morales, B., Sánchez, V., Mena, M. A., & Giménez Roldán, S. (1997). [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]. Neurologia (Barcelona, Spain), 12(4), 145-56.
García de Yébenes J, et al. [The Effect of Controlled Release of DOPA and Carbidopa On Clinical Response and Plasma Pharmacokinetics of DOPA in Parkinsonian Patients]. Neurologia. 1997;12(4):145-56. PubMed PMID: 9235023.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [The effect of controlled release of DOPA and carbidopa on clinical response and plasma pharmacokinetics of DOPA in parkinsonian patients]. AU - García de Yébenes,J, AU - Mateo,D, AU - Pino,M A, AU - Cordero,M, AU - Pastor,M, AU - Chacón,J, AU - Morales,B, AU - Sánchez,V, AU - Mena,M A, AU - Giménez Roldán,S, PY - 1997/4/1/pubmed PY - 1997/4/1/medline PY - 1997/4/1/entrez SP - 145 EP - 56 JF - Neurologia (Barcelona, Spain) JO - Neurologia VL - 12 IS - 4 N2 - This is a multicentric double blind comparison of the effects of standard and slow release levodopa + carbidopa formulations in patients with Parkinson's disease. Sixty four patients with simple fluctuations were included and 43 finished the study. The study had three phases: a) optimal dose findings phase with standard levodopa + carbidopa; b) open label, cross over study with the two formulations, and c) double blind, parallel investigation. The following results were obtained. There was not a difference in the severity of disability according to UPDRS, part 3, scores though the subjective impressions of patients were in favor of standard formulations. The Sustained release levodopa + carbidopa produced significant improvement of dystonia in off period, pain due to akinesia in off and the number of hours in off and the quality and latency of sleep. In addition there was a tendency in favor of slow release compounds for early morning akinesia, global effect and impression of the examining physician. Low protein diet improved the kinetics of levodopa and the clinical response with both formulations. The clinical usefulness of standard and slow release levodopa + carbidopa formulation should be weighted according to individual problems of patients with Parkinson's disease. SN - 0213-4853 UR - https://www.unboundmedicine.com/medline/citation/9235023/[The_effect_of_controlled_release_of_DOPA_and_carbidopa_on_clinical_response_and_plasma_pharmacokinetics_of_DOPA_in_parkinsonian_patients]_ L2 - https://medlineplus.gov/parkinsonsdisease.html DB - PRIME DP - Unbound Medicine ER -